1st International Symposium on Deuterium Depletion was held on 13-14 May 2010 in Budapest, Hungary. The conference programme focused on the advances in the research and clinical application of deuterium depletion, its present and future role in anticancer research and oncotherapy, diabetes research and anti-aging. The conference's goal was to provide a scientific forum for all stakeholders of this new field of science and enable the interactive exchange of state-of-the-art knowledge. The conference focused on the evidence-based benefits of deuterium depletion, confirmed its significant antitumor effect, and suggested its application in other indication fields.
At the 1st International Symposium on Deuterium Depletion leading scientists from five countries (Hungary, Romania, USA, Russia, Iran) presented and discussed current advances in the research and various application of deuterium depletion. New scientific evidences that support the efficacy of deuterium depleted substances were conferred. The inventor of deuterium depletion, Gábor Somlyai, PhD gave an overall picture on the results of the twenty-year research in his four papers and on the different applications of this new treatment modality in the field of veterinary science and human clinical practice. Daiana Silva de ávila, PhD, arrived from Vanderbilt Medical Center, Nashville TN, USA, presented that manganese caused shortened lifespan in worms was reversed by deuterium depleted water, DDW showed anti-aging property. Professor Laszlo G. Boros (UCLA), the scientific director of SiDMAP, Inc. presented that based on their observations, it became evident that decreased deuterium to hydrogen ratios regulate sterol and fatty acid precursor synthesis, which likely affects the rate of divisions and cellular proliferation via limited reductive synthesis and new membrane formation. Prof. Ebrahim Azizi (School of Advanced Medical Sciences, Tehran University of Medical Sciences, Iran) and his co-authors found a significant increase in apoptosis induction of HT-29 cells following exposure to D-depleted Doxorubicin variants in comparison to normal Doxorubicin. These data also supported the previously reported findings on significant potential of DDW on cancer cells to enhance the effectiveness of chemotherapy. Further to its scientific content, 1st International Symposium on Deuterium Depletion was a networking event, a unique opportunity to meet all the stakeholders of deuterium depletion. It was a good opportunity to meet those who influenced the past, influence the present and most importantly will enable the future of deuterium depletion by means of basic and applied research or clinical trials. Initiation of cross-boarder co-operations between scientists and institutions was also facilitated during the conference.
The organizer HYD LLC. develops pharmaceutical and consumer products based on the recognition that the naturally occuring deuterium has a central role in the regulation of cell processes. Deuterium depletion is a completely original approach to inhibit the growth of cancer cells in the body and to influence other physiological processes like glucose metabolism.
In the early nineties, Hungarian molecular biologist, Gábor Somlyai, PhD recognized, that the shortage of deuterium can cause significant changes in living organisms. The most important outcome of this research carried out with deuterium-depleted water (DDW) was that tumour cells proved to be extremely sensitive to the withdrawal of D. There is conclusive clinical evidence that the combination of conventional therapy with DDW can result in a 2-3 fold increase in median survival time (MST). Recent results show that the depletion of deuterium induces changes in the expression of genes, which play an already recognized role in the pathology of most cancer types. The first anticancer drug based on deuterium depletion (Vetera-DDW-25® A.U.V.) was registered for the treatment of house-hold pets with tumors in 1999, it verified an efficacy rate of 70-80% in veterinary practice. For human consumption Preventa® deuterium depleted drinking water is on the market since 2000. In 2010, HYD LLC. plans to start a phase II clinical trial to investigate the antitumor effect of DDW in symptomatic, previously untreated chronic lymphocytic leukemia (CLL).
Recently, pharmacological industry started to develop and commercialize deuterium-containing medicines (GSK-Concert Pharmaceutical). Strategic replacement of hydrogen atoms in therapeutics with deuterium could positively influence efficacy and side effect profiles of drugs.
HYD's approach to deuterium depletion of water and other molecules has broad potential to enhance the effectiveness of the presently available oncotherapies and result in innovative new medicines and consumer products for the treatment and prevention of cancer. Recent research shows that the application of deuterium depletion can cover other indication fields, like diabetes.
Research and drug development based on deuterium depletion is an exceptional investment opportunity, HYD is seeking for private equity or venture capital investors to finance the research and drug registration.
HYD LLC for Cancer Research and Drug Development